查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1873992

生物防御市场

Biodefense Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024年，生物防御市场规模约为147.7亿美元，预计到2031年将成长至216.2亿美元，2031年至2032年的年复合成长率（CAGR）为6.1%。巨量资料和人工智慧的融合为开展各种生物威胁的技术评估提供了重要机会，并为追踪疾病爆发提供了绝佳机会。因此，预测分析可望变革生物防御领域，成为该市场的关键趋势。

生物防御市场分析

基因工程和生物技术的最新进展使得改造致命病毒和自然存在的病毒变得更加容易，这可能加剧病毒的危害。人们对生物攻击和疫情爆发的灾难性后果的认识不断提高，导致对生物防御解决方案的需求激增。世界各国政府都在大力投资生物防御能力建设，这推动了市场成长。技术进步和对研发的日益重视促成了先进创新型生物防御解决方案的问世。合成生物学、基因组学和资料分析等技术创新推动了这些解决方案的开发，增强了识别、表征和缓解生物威胁的能力。此外，政府、国防部门和商业实体之间的合作促进了综合生物防御战略的製定，进一步推动了市场成长。

生物防御市场概览

生物防御涵盖一系列旨在保护国家免受生物威胁或传染病侵害的活动和技术。它应对与流行病、生物恐怖主义和其他生物突发事件相关的风险。在美国，联邦政府协调各项计画并分配预算，以预防、应对和管理生物灾害。美国的生物防御计划，即国家生物防御战略，涉及各级政府与私营机构和其他利益相关者的合作，共同进行生物防御活动。此外，加拿大国家传染病合作中心透过网路研讨会、播客、线上资源和出版物，向政策制定者、公共卫生官员、卫生检查员和其他人员提供有关新兴传染病的最新资讯。因此，旨在加强生物防御体系的政府措施预计将在预测期内推动市场成长。

战略洞察

生物防御市场驱动因素与机会

政府扶持措施推动市场成长

已开发国家政府正在实施各种措施和预防策略来应对生物恐怖主义威胁。在联邦政府投入增加、技术进步和公众意识提高的推动下，各国储备了疫苗和生物威胁检测工具，以保障公众健康。主要行业参与者的存在也对市场产生了积极影响。 2018年，美国政府推出了《国家生物防御战略及实施计画》，以及《国家安全战略》、《国家国防战略》、《国家反恐战略》和《国家反大规模杀伤性武器战略》，所有这些战略都强调了生物安全和生物防御的重要性。

在印度等新兴市场，国防研究与发展组织等机构正在研发应对生物攻击的对策，并大力加强军队应对此类威胁的准备。过去二十年来，全球对生物恐怖主义的认识日益提高，同时，旨在应对这些威胁的各种提案和会议也层出不穷，这极大地推动了对生物防御的需求。全球政府的各项措施为生物防御领域的企业创造了机会，从而促进了市场成长。

技术应用普及将促进市场成长

包括用于法医病原体检测的基因晶片、资料库管理系统、生物防御药物研发中的先进检测硬体以及奈米技术在内的多种技术的日益普及，正在增强生物防御能力。许多此类技术被单独或组合使用，以创建和开发各种生物防御工具。目前，基因工程是生物防御中最关键的技术，它涉及对遗传物质的人工操作和转移。此外，基因疗法有望用于治疗多种疾病。许多专家预测，未来的生物武器可能是客製化生物武器，而这项技术可能在发现许多目前未知疾病的治疗方法方面发挥关键作用。分子生物学和基因工程的最新进展催生了疫苗研发的新策略，这很可能在未来为生物防御市场创造巨大的成长机会。

生物防御市场报告細項分析

生物防御市场分析按产品类型细分。

  • 市场依疾病类别分为炭疽、天花、肉毒桿菌中毒、辐射/核辐射等。 2023年，炭疽病细分市场占据最大市场份额，预计在预测期内将保持最高的复合年增长率。

按地域分類的生物防御市场占有率分析

生物防御市场报告的地理分析分为五个区域：北美、亚太、欧洲、中东和非洲以及南美和中美洲。

北美一直是生物防御市场的领先地区。对人类、动物和环境的生物威胁是美国及其国民面临的最紧迫挑战之一。随着这些生物威胁的不断升级，美国正优先提升自身能力，并将应对生物威胁和生物恐怖主义的准备工作视为国家安全的关键组成部分。该地区对国家安全的高度重视、完善的医疗保健体係以及强大的研发能力，都促进了市场成长。由于政府的积极倡议、与行业参与者的合作以及对生物恐怖主义威胁的高度防范，该地区已在生物防御技术（包括治疗方法、疫苗和检测系统）方面进行了大量投资。

由生物医学高级研究与发展局（BARDA）、国家过敏和传染病研究所（NIAID）、疾病管制与预防中心（CDC）、美国卫生与公众服务部（ASPR）和美国食品药物管理局（FDA）等机构实施的生物防御策略也促进了该地区的成长。美国军方和民事机构对生物防御的大量投入是推动该地区收入份额领先的另一个关键因素。

预计未来几年亚太地区将实现最高的复合年增长率，这主要得益于研发投入的增加、生物防御的重要性以及可能导致突发事件的危险生物材料威胁的日益加剧。该地区易受传染病侵袭，人口众多，加上其拥有先进的医疗基础设施，因此对生物防御产品和技术的需求不断增长。

生物防御市场报告范围

生物防御市场新闻及最新进展

生物防御市场评估是基于从一手和二手研究中收集的定性和定量资料，包括重要的企业出版物、协会资料和资料库。以下是生物防御市场的一些最新发展和策略：

  • 2022年2月，Appili Therapeutics公司宣布，已从美国国防部透过国防威胁降低局联合科学技术办公室获得超过1000万美元的资金，用于推进其生物防御候选疫苗ATI-1701的研发。该疫苗旨在预防土拉弗朗西斯菌感染。预计这笔资金将增强该公司在生物防御市场的份额并促进其业务成长。 （资料来源：Appili Therapeutics，新闻稿，2022）
  • 2022年9月，Emergent BioSolutions Inc.与Chimerix, Inc.最终达成协议，取得TEMBEXA（brincidofovir）的全球独家经销权。 TEMBEXA是第一个获得美国FDA核准用于治疗所有年龄层天花患者的口服抗病毒药物。 （资料来源：Emergent BioSolutions Inc.，新闻稿，2022年）
  • 2023年7月，Emergent BioSolutions公司生产的CYFENDUS（炭疽疫苗吸附佐剂，原名AV7909）获得美国FDA批准，用于18至65岁人群在疑似或确诊接触炭疽桿菌后进行暴露后预防，需与推荐的抗菌药物联合使用。 （资料来源：Emergent BioSolutions公司，新闻稿，2023年）

生物防御市场报告涵盖范围和成果

这份题为《生物防御市场规模及预测（2021-2031）》的报告对市场进行了全面分析，涵盖以下领域：

  • 涵盖范围内所有关键细分市场的全球、区域和国家层面的市场规模和预测
  • 市场动态，例如驱动因素、限制因素和关键机会
  • 未来主要趋势
  • 详细的PEST/波特五力模型与SWOT分析
  • 全球及区域市场分析，涵盖关键市场趋势、主要参与者、法规及最新发展动态
  • 产业格局和竞争分析，包括市场集中度、热力图分析、主要参与者和最新发展动态
  • 公司详细概况

目录

第一章：引言

第二章：生物防御市场及主要结论

第三章：研究方法

  • 覆盖范围
  • 二手研究
  • 初步研究

第四章：生物防御与市场格局

  • 概述
  • PEST分析
    • 北美洲
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美洲和中美洲
  • 专家意见

第五章：全球生物防御市场及产业动态

  • 关键驱动因素
    • 有利的政府倡议
    • 自然发生的疫情数量增加
    • 生物武器和核子洲际弹道飞弹的威胁日益加剧。
  • 主要市场限制因素
    • 发展中经济体及欠发达经济体政府研发投入不足
  • 主要市场机会
    • 技术应用日益普及
  • 未来趋势
    • 预测分析将重塑生物防御市场
  • 影响分析

第六章：生物防御市场及全球分析

  • 全球生物防御市场收入预测与分析
  • 全球生物防御市场（依地域划分）－预测与分析
  • 关键参与者的市场定位

第七章：生物防御市场分析及产品分类

  • 概述
  • 生物防御市场收入份额（按产品划分）（2024 年和 2031 年）
  • 炭疽病
  • 天花
  • 肉毒桿菌中毒
  • 辐射/核能
  • 其他的

第八章：生物防御市场及地理分析

    • 概述
    • 北美：生物防御市场、收入及至2031年预测
    • 北美：生物防御市场（按产品划分），2024 年和 2031 年
    • 北美：生物防御市场（按国家划分），2024 年和 2031 年（%）
    • 美国：生物防御市场、收入及至2031年预测
      • 美国：生物防御市场、收入及至2031年预测
      • 美国：生物防御市场（按产品类型划分），2024 年和 2031 年
    • 加拿大：生物防御市场、收入及至2031年预测
      • 加拿大：生物防御市场、收入及至2031年预测
      • 加拿大：生物防御市场（按产品类型划分），2024 年和 2031 年
    • 墨西哥：生物防御市场、收入及至2031年预测
      • 墨西哥：生物防御市场、收入及至2031年预测
      • 墨西哥：生物防御市场（按产品类型划分），2024 年和 2031 年
  • 欧洲：生物防御市场
    • 概述
    • 欧洲：生物防御市场－收入及至2031年的预测
    • 欧洲：生物防御市场（依产品划分），2024 年和 2031 年
    • 欧洲：生物防御市场（按国家划分），2018 年和 2031 年（%）
    • 德国：生物防御市场、收入及至2031年的预测
      • 德国：生物防御市场、收入及至2031年的预测
      • 德国：生物防御市场（依产品类型划分），2024 年和 2031 年
    • 英国：生物防御市场、收入及至2031年预测
      • 英国：生物防御市场、收入及至2031年预测
      • 英国：生物防御市场（依产品类型划分），2024 年和 2031 年
    • 法国：生物防御市场、收入及至2031年预测
      • 法国：生物防御市场、收入及至2031年预测
      • 法国：生物防御市场（依产品类型划分），2024 年和 2031 年
    • 西班牙：生物防御市场、收入及至2031年预测
      • 西班牙：生物防御市场、收入及至2031年预测
      • 西班牙：生物防御市场（按产品类型划分），2024 年和 2031 年
    • 义大利：生物防御市场、收入及至2031年预测
      • 义大利：生物防御市场、收入及至2031年预测
      • 义大利：生物防御市场（依产品类型划分），2024 年和 2031 年
  • 亚太地区：生物防御市场
    • 概述
    • 亚太地区：生物防御市场－收入及至2031年预测
    • 亚太地区：生物防御市场（按产品划分），2024 年和 2031 年
    • 亚太地区：生物防御市场（按国家/地区划分），2018 年和 2031 年（%）
    • 中国：生物防御市场、收入及至2031年预测
      • 中国：生物防御市场、收入及至2031年预测
      • 中国：生物防御市场（依产品类型划分），2024 年和 2031 年
    • 日本：生物防御市场、收入及至2031年预测
      • 日本：生物防御市场、收入及至2031年预测
      • 日本：生物防御市场（依产品类型划分），2024 年和 2031 年
    • 印度：生物防御市场、收入及至2031年预测
      • 印度：生物防御市场、收入及至2031年预测
      • 印度：生物防御市场（按产品类型划分），2024 年和 2031 年
    • 韩国：生物防御市场、收入及至2031年预测
      • 韩国：生物防御市场、收入及至2031年预测
      • 韩国：生物防御市场（按产品类型划分），2024 年和 2031 年
    • 澳洲：生物防御市场、收入及至2031年的预测
      • 澳洲：生物防御市场、收入及至2031年预测
      • 澳洲：生物防御市场（依产品类型划分），2024 年和 2031 年
  • 南美洲和中美洲：生物防御市场
    • 概述
    • 南美洲和中美洲：生物防御市场－收入及至2031年的预测
    • 南美洲和中美洲：生物防御市场（按产品划分），2024 年和 2031 年
    • 南美洲和中美洲：生物防御市场（按国家划分），2018 年和 2031 年（%）
    • 巴西：生物防御市场、收入及至2031年预测
      • 巴西：生物防御市场、收入及至2031年预测
      • 巴西：生物防御市场（依产品类型划分），2024 年和 2031 年
    • 阿根廷：生物防御市场、收入及至2031年预测
      • 阿根廷：生物防御市场、收入及至2031年预测
      • 阿根廷：生物防御市场（按产品类型划分），2024 年和 2031 年

第九章：新冠肺炎疫情对全球生物防御市场的影响

  • 北美洲
  • 欧洲
  • 亚太
  • MEA
  • 萨姆

第十章：生物防御市场及产业概况

  • 概述
  • 2016-2020年生物防御市场成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第十一章：公司简介

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • pluristem

第十二章：附录

简介目录
Product Code: TIPRE00005377

In 2024, the biodefense market was valued at approximately US$ 14.77 billion and is anticipated to grow to US$ 21.62 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.1% from 2031 to 2031. The integration of big data and artificial intelligence presents significant opportunities for conducting technical evaluations of various biothreats and offers an exceptional chance to track disease outbreaks. Consequently, predictive analytics is poised to transform the biodefense sector, emerging as a pivotal trend in the market.

Biodefense Market Analysis

Recent advancements in genetic engineering and biotechnology have made it easier to modify lethal and naturally occurring viruses, potentially increasing their harmful effects. The growing awareness of the catastrophic consequences of biological attacks and outbreaks has led to a heightened demand for biodefense solutions. Governments worldwide are investing heavily in biodefense capabilities, which is driving market growth. Technological advancements and a stronger focus on research and development have resulted in the introduction of advanced and innovative biodefense solutions. The development of these solutions is fueled by technological innovations such as synthetic biology, genomics, and data analytics, which enhance the ability to identify, characterize, and mitigate biological threats. Furthermore, collaborations among government, defense, and commercial entities have facilitated the creation of comprehensive biodefense strategies, further propelling market growth.

Biodefense Market Overview

Biodefense encompasses a variety of activities and technologies aimed at safeguarding a nation from biological threats or infectious diseases. It addresses the risks associated with pandemics, bioterrorism, and other biological emergencies. In the United States, the federal government coordinates programs and allocates budgets to prevent, respond to, and manage biological disasters. The US biological defense program, known as the National Biodefense Strategy, involves collaborative efforts across various government levels in partnership with private organizations and other stakeholders to conduct biodefense activities. Additionally, Canada's National Collaborating Centre for Infectious Diseases provides up-to-date information on emerging infectious diseases to policymakers, public health officials, health inspectors, and others through webinars, podcasts, online resources, and publications. Therefore, government initiatives aimed at enhancing the biodefense system are expected to support market growth during the forecast period.

Strategic Insights

Biodefense Market Drivers and Opportunities

Supportive Government Initiatives to Propel Market Growth

Governments in developed countries are implementing various measures and preventive strategies to counter bioterrorism threats. They maintain stockpiles of vaccines and bio-threat detection tools to safeguard public health, driven by increased federal funding, technological advancements, and heightened public awareness. The presence of major industry players also positively impacts the market. In 2018, the US government introduced the National Biodefense Strategy and Implementation Plan, along with the National Security Strategy, National Defense Strategy, National Counterterrorism Strategy, and National Counter WMD Strategy, all emphasizing biosecurity and biodefense.

In emerging markets like India, organizations such as the Defense Research and Development Organization are developing countermeasures against biological attacks, with significant efforts to prepare military forces for such threats. Over the past two decades, there has been a growing focus on raising awareness about bioterrorism globally, alongside various proposals and meetings aimed at combating these threats, which significantly drives the demand for biodefense. Global government initiatives create opportunities for companies in the biodefense sector, thereby fostering market growth.

Increased Technology Adoption to Boost Market Growth

The rising adoption of technologies, including gene chips for pathogen detection in forensic applications, database management systems, advanced detection hardware in biodefense drug development, and nanotechnology, is enhancing biological defense capabilities. Many of these technologies are utilized independently or in combination to create and develop various biodefense tools. Currently, genetic engineering is the most critical technology for biodefense, involving the artificial manipulation and transfer of genetic material. Additionally, gene therapy holds promise for treating various diseases. Many experts predict that future bioweapons may be designer bioweapons, and this technology could play a crucial role in discovering cures for many currently unknown diseases. Recent advancements in molecular biology and genetic engineering have led to new strategies for vaccine development, likely creating substantial growth opportunities for the biodefense market in the future.

Biodefense Market Report Segmentation Analysis

The biodefense market analysis is segmented by product.

  • The market is categorized into anthrax, smallpox, botulism, radiation/nuclear, and others. The anthrax segment accounted for the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period.

Biodefense Market Share Analysis by Geography

The geographic analysis of the biodefense market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has been the leading region in the biodefense market. The biological threats to humans, animals, and the environment are among the most pressing challenges faced by the US and its national community. As these biological threats continue to escalate, the US is prioritizing the enhancement of its capabilities and considers preparedness for biothreats and bioterrorism as a critical aspect of national security. The region's strong focus on national security, well-established healthcare systems, and robust research and development capabilities contribute to market growth. Due to proactive government initiatives, collaborations with industry players, and a high level of preparedness against bioterrorism threats, significant investments in biodefense technologies, including therapeutics, vaccines, and detection systems, have been made in this region.

Biodefense strategies implemented by organizations such as BARDA, NIAID, CDC, ASPR, and the FDA are also contributing to the region's growth. Substantial funding from US military and civilian agencies for biodefense is another key factor driving the region's leading revenue share.

Asia Pacific is projected to experience the highest CAGR in the coming years, supported by increasing R&D investments, the importance of biodefense, and the rising threat of hazardous biological materials that can lead to emergencies. The region's vulnerability to infectious diseases and its large population have heightened the demand for biodefense products and technologies, along with the presence of advanced healthcare infrastructure.

Biodefense Market Report Scope

Biodefense Market News and Recent Developments

The biodefense market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the biodefense market:

  • In February 2022, Appili Therapeutics Inc. announced it received over US$ 10 million in funding from the US Department of Defense, through the Joint Science and Technology Office of the Defense Threat Reduction Agency, to advance its biodefense vaccine candidate, ATI-1701, which aims to prevent infection with Francisella tularensis. This funding is expected to enhance the company's presence and growth in the biodefense market. (Source: Appili Therapeutics, Press Release, 2022)
  • In September 2022, Emergent BioSolutions Inc. finalized its agreement with Chimerix, Inc. to acquire exclusive global rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the US FDA for treating smallpox across all age groups. (Source: Emergent BioSolutions Inc., News Release, 2022)
  • In July 2023, Emergent BioSolutions Inc. received US FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis against disease following suspected or confirmed exposure to Bacillus anthracis in individuals aged 18 to 65, when administered alongside recommended antibacterial drugs. (Source: Emergent BioSolutions Inc., News Release, 2023)

Biodefense Market Report Coverage and Deliverables

The report titled "Biodefense Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis covering key market trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • Detailed company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Biodefense Market and By Product
    • 1.3.2 Global Biodefense Market and By Geography

2. Biodefense Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Biodefense and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
    • 4.2.4 Middle East and Africa
    • 4.2.5 South and Central America
  • 4.3 Expert Opinion

5. Global Biodefense Market and Industry Dynamics

  • 5.1 Key Drivers
    • 5.1.1 Presence of Favourable Government Initiatives
    • 5.1.2 Increase in the Number of Naturally Occurring Outbreaks
    • 5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM
  • 5.2 Key Market Restraints
    • 5.2.1 Low R and D Funding by Government in Developing and Underdeveloped Economies
  • 5.3 Key Market Opportunities
    • 5.3.1 Increased Adoption of Technologies
  • 5.4 Future Trends
    • 5.4.1 Predictive Analytics to Reshape Biodefense Market
  • 5.5 Impact Analysis

6. Biodefense Market and Global Analysis

  • 6.1 Global Biodefense Market Revenue Forecast And Analysis
  • 6.2 Global Biodefense Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Biodefense Market Analysis and By Product

  • 7.1 Overview
  • 7.2 Biodefense Market Revenue Share, by Product (2024 and 2031)
  • 7.1 Anthrax
    • 7.1.1 Overview
    • 7.1.2 Anthrax: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Small pox
    • 7.2.1 Overview
    • 7.2.2 Small pox: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Botulism
    • 7.3.1 Overview
    • 7.3.2 Botulism: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Radiation/Nuclear
    • 7.4.1 Overview
    • 7.4.2 Radiation/Nuclear: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Biodefense Market and Revenue and Forecast to 2031 (US$ Million)

8. Biodefense Market and Geographic Analysis

    • 8.1.1 Overview
    • 8.1.2 North America: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
    • 8.1.3 North America: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.1.4 North America: Biodefense Market, by Country, 2024 and 2031 (%)
    • 8.1.5 US: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.5.1 US: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.5.2 US: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.1.6 Canada: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.6.1 Canada: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.6.2 Canada: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.1.7 Mexico: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.7.1 Mexico: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.1.7.2 Mexico: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
  • 8.2 Europe: Biodefense Market
    • 8.2.1 Overview
    • 8.2.2 Europe: Biodefense Market - Revenue and Forecast to 2031 (USD Million)
    • 8.2.3 Europe: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.2.4 Europe: Biodefense Market, by Country, 2018 and 2031 (%)
    • 8.2.5 Germany: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.5.1 Germany: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.5.2 Germany: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.6 UK: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.6.1 UK: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.6.2 UK: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.7 France: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.7.1 France: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.7.2 France: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.8 Spain: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.8.1 Spain: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.8.2 Spain: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.2.9 Italy: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.9.1 Italy: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.2.9.2 Italy: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
  • 8.3 Asia Pacific: Biodefense Market
    • 8.3.1 Overview
    • 8.3.2 Asia Pacific: Biodefense Market - Revenue and Forecast to 2031 (USD Million)
    • 8.3.3 Asia Pacific: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.3.4 Asia Pacific: Biodefense Market, by Country, 2018 and 2031 (%)
    • 8.3.5 China: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.5.1 China: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.5.2 China: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.6 Japan: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.6.1 Japan: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.6.2 Japan: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.7 India: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.7.1 India: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.7.2 India: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.8 South Korea: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.8.1 South Korea: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.8.2 South Korea: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.3.9 Australia: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.9.1 Australia: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.3.9.2 Australia: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
  • 8.4 South and Central America: Biodefense Market
    • 8.4.1 Overview
    • 8.4.2 South and Central America: Biodefense Market - Revenue and Forecast to 2031 (US$ Million)
    • 8.4.3 South and Central America: Biodefense Market, by Product, 2024 and 2031 (USD Million)
    • 8.4.4 South and Central America: Biodefense Market, by Country, 2018 and 2031 (%)
    • 8.4.5 Brazil: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.5.1 Brazil: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.5.2 Brazil: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)
    • 8.4.6 Argentina: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.6.1 Argentina: Biodefense Market and Revenue and Forecast to 2031 (USD Million)
      • 8.4.6.2 Argentina: Biodefense Market, by Product Type, 2024 and 2031 (USD Million)

9. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BIODEFENSE MARKET

  • 9.1 North America: Impact assessment of COVID-19 Pandemic
  • 9.2 Europe: Impact assessment of COVID-19 Pandemic
  • 9.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic
  • 9.4 MEA: Impact assessment of COVID-19 Pandemic
  • 9.5 SAM: Impact assessment of COVID-19 Pandemic

10. Biodefence Market andIndustry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in The Biodefence Market, 2016-2020
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. COMPANY PROFILES

  • 11.1 Bavarian Nordic
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Alnylam Pharmaceuticals, Inc.
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 SIGA Technologies
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Emergent BioSolutions Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Cleveland Bio Labs
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Dynavax Technologies
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Elusys Therapeutics, Inc.
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Soligenix
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Altimmune
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 pluristem
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms